167 results found in news
news
CareAcross content
CareAcross
Posted about 5 years ago
Drugs used in prostate gland removal linked to cancer outcome, study finds
Opioids (painkillers commonly given during and after surgery) may suppress the immune system's ability to fight cancer cells, leading to a suggestion that supplementing general anesthesia with a spinal or epidural painkiller before a radical prostatectomy reduces a patient's need for opioids after surgery, and this finding was associated with a lower risk of cancer recurrence.
Read full article
CareAcross content
CareAcross
Posted about 5 years ago
Prostate cancer stem cells found to be moving target
Researchers have found that prostate cancer can develop in one type of stem cell, then evolve to be maintained by a stem cell that looks very different, making prostate cancer stem cells a "moving target" for treatments. The breakthrough discovery connects directly to the development of future therapeutics that target cancer and was published in the Proceedings of the National Academy of Sciences.
Read full article
CareAcross content
CareAcross
Posted about 5 years ago
Weight at time of diagnosis linked to prostate cancer mortality
Men who are overweight or obese when they are diagnosed with prostate cancer are more likely to die from the disease than men who are of healthy weight, according to a Kaiser Permanente study published in the journal Obesity Research & Clinical Practice. In patients with more aggressive forms of prostate cancer, the researchers also found an even stronger correlation between obesity and mortality.
Read full article
CareAcross content
CareAcross
Posted about 5 years ago
ASCO highlights five cancer treatments routinely performed despite lack of evidence
The American Society of Clinical Oncology (ASCO) announced its second “Top Five” list of opportunities to improve the quality and value of cancer care. Published in the Journal of Clinical Oncology (JCO), ASCO’s second Top Five list was released as part of the Choosing Wisely® campaign, sponsored by the ABIM Foundation, to encourage conversations between physicians and patients aimed at curbing the use of certain tests and procedures that are not supported by clinical research. One of the first nine medical societies to join the Choosing Wisely campaign, ASCO issued its first Top Five list in April 2012.
Read full article
CareAcross content
CareAcross
Posted about 5 years ago
ASTRO 2013: Long-term hormonal therapy in intermediate-risk prostate cancer patients does not improve overall survival
A secondary analysis of a historic prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
Read full article